TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT01271478

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: captopril plus placebo
Description: This group will receive captopril 50 mg/day (1 tablet of 25 mg orally twice a day) plus 1 tablet of placebo orally twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: telmisartan plus placebo
Description: Patients of this group will receive telmisartan 80 mg/day (1 tablet 40 mg orally twice a day) plus 1 tablet of placebo twice a day

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Telmisartan plus Captopril
Description: Patients of this group will receive captopril 50 mg/day (1 tablet 25 mg orally twice a day) plus telmisartan 80 mg/day (1 tablet 40 mg orally twice a day)

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients in this group will receive 2 tablets of placebo (starch) twice a day.
Study: NCT00518453

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Surface antigen inactivated influenza vaccine
Description: 1 dose of Fluvirin 2007/2008 Northern Hemisphere vaccine composition
Study: NCT02526615

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Rosiglitazone
Description: Patients received either placebo, metformin or rosiglitazone

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Metformin
Description: Patients received either placebo, metformin or rosiglitazone

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Patients received either placebo, metformin or rosiglitazone
Study: NCT00544128

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: lamivudine, abacavir , ritonavir, atazanavir
Description: Patients are treated with Epzicom (lamivudine 300mg and abacavir 600mg) combined with ritonavir 100mg boosted atazanavir 300mg

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: emtricitabine, tenofovir, ritonavir, atazanavir
Description: Patients are treated with Truvada (emtricitabine 200mg and tenofovir 300mg) combined with ritonavir 100mg boosted atazanavir 300mg.
Study: NCT02832804

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: transcranial Direct Current Stimulation
Description: Experimental: anodal stimulation (2mA) for 20 minutes Active Comparator: cathodal stimulation (2mA) for 20 minutes Sham Comparator: sham stimulation (2mA) for 15 seconds

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: transcranial Direct Current Stimulation
Description: Experimental: anodal stimulation (2mA) for 20 minutes Active Comparator: cathodal stimulation (2mA) for 20 minutes Sham Comparator: sham stimulation (2mA) for 15 seconds

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: transcranial Direct Current Stimulation
Description: Experimental: anodal stimulation (2mA) for 20 minutes Active Comparator: cathodal stimulation (2mA) for 20 minutes Sham Comparator: sham stimulation (2mA) for 15 seconds
Study: NCT03808272

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HOT AXIOS Stent and Electrocautery- Enhanced Delivery System
Description: The HOT AXIOS Stent and Electrocautery- Enhanced Delivery System is indicated for use to facilitate transgastric or transduodenal endoscopic drainage of a pancreatic pseudocyst or a walled-off necrosis with ≥ 70% fluid content.
Study: NCT01212133

Intervention type: DRUG
Intervention: liraglutide
Description: Self-administered subcutaneously (under the skin) once daily at any time, independent of meals, in the abdomen, thigh or upper arm.
Study: NCT01306877

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: EEA Hemorrhoid and Prolapse Stapling Set
Description: Surgical device

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Endosurgery Proximate PPH03 Stapling Set
Description: Surgical device
Study: NCT04123028

Intervention type: OTHER
Intervention: observatory
Description: observation for 1 year period

Intervention type: OTHER
Intervention: observatory
Description: observation for 1 year period
Study: NCT02948283

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin Hydrochloride
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pharmacological Study
Description: Correlative studies

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ritonavir
Description: Given PO

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Quality-of-Life
Description: Ancillary studies

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Questionnaire
Description: Ancillary studies
Study: NCT01915966

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Cardamom, ginger and orange juice gelatin
Description: Patients will receive the recipe of the gelatin, with detailed instructions to prepare it at home, and the necessary ingredients for the gelatin. If necessary, they will be helped in the preparation of an initial batch that should last for one week of treatment. Patients will be instructed to consume the gelatin candy as necessary to alleviate the dry mouth sensation

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Camomile infusion with lemon juice
Description: Patients will receive instructions to prepare the infusion at home, and the necessary ingredients. Patients will be instructed to ingest the infusion as necessary to alleviate the dry mouth sensation.
Study: NCT04186689

Intervention type: OTHER
Intervention: Routine Dental Examination
Description: Routine dental examination for the pre-school children Questionnaire for their mothers

Intervention type: OTHER
Intervention: Routine Dental Examination
Description: Routine dental examination for the pre-school children Questionnaire for their mothers

Intervention type: OTHER
Intervention: Routine Dental Examination
Description: Routine dental examination for the pre-school children Questionnaire for their mothers
Study: NCT02003339

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Additional RMIs
Study: NCT03000270

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Impella unloading prior to PPCI
Description: Impella unloading prior to PPCI

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Impella unloading prior to PPCI
Description: Impella unloading prior to PPCI
Study: NCT00890188

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: THALIDOMIDE and UFUR
Description: T: Thalidomide (50): 150 mg/d ((1# tid) U: UFUR(100) 300 mg/d (1# tid) 28 days for one cycle
Study: NCT03825471

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: electrotherapy
Description: Cranial electrotherapy stimulation

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: electrotherapy
Description: Cranial electrotherapy stimulation

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Opioid Anesthetics
Description: consumption of opioids during general anesthesia

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Opioid Anesthetics
Description: consumption of opioids during general anesthesia

Intervention type: PROCEDURE
Group type: PLACEBO_COMPARATOR
Intervention: colon cancer surgery
Description: laparoscopic colon cancer surgery

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: colon cancer surgery
Description: laparoscopic colon cancer surgery
Study: NCT02906462

Intervention type: OTHER
Group type: OTHER
Intervention: Early consideration of vulnerability
Description: One day training with the provision of vulnerability criteria inciting an early reflection of the level of therapeutic engagement; sheets available on the internet computer support collegial reflection and traceability of decisions to limit and stop treatments, incorporating the provisions of law known Leonetti

Intervention type: OTHER
Group type: OTHER
Intervention: Usual practices
Description: the centres applies their usual practices
Study: NCT00450775

Intervention type: DRUG
Group type: OTHER
Intervention: Dermatix Q
Description: Dermatix Q applied twice daily
Study: NCT00505882

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pramlintide
Description: Pramlintide will be started at 15 mcg (2.5 units) subcutaneously immediately prior to major meals and it will be increased by 15mcg every 3 days as tolerated (i.e. nausea, vomiting, upset stomach) to a maximum dose of 60 mcg (10 units) before meals. If significant nausea persists at 45 or 60 mcg level, the dose should be decreased to 30 mcg (5 units) before meals. If the 30 mcg dose is not tolerated, investigator will evaluate for possibility of withdrawing the pramlintide. The dose of preprandial short acting insulin (eg: Novolog/Humalog) will be reduced by 30 to 50% at the start of pramlintide 15 mcg (2.5 units) and then will be adjusted every time the dose of pramlintide is increased by 15 mcg (2.5 units) as needed based on blood glucose readings.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glargine

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Glargine

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lispro

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Lispro

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Aspart

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aspart
Study: NCT03245229

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan
Description: Capsule for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Aprocitentan
Description: Capsule for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Tablet for oral administration

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Rosuvastatin
Description: Tablet for oral administration
Study: NCT03358537

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Clear Liquid Diet
Description: Clear liquid diet was compared with low-residue diet, in combination with Poliethylene Glycol in each group

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: Low-residue Diet
Description: Clear liquid diet was compared with low-residue diet, in combination with Poliethylene Glycol in each group
Study: NCT02495103

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib
Description: PHASE I: Vandetanib by mouth (PO) daily at 300mg in combination with escalating doses of metformin.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Metformin
Description: Phase I: Metformin starting dose 250mg by mouth (PO) daily in combination with Vandetanib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vandetanib/Metformin
Description: Phase II: Vandetanib and metformin by mouth (PO) daily at determined maximum tolerated dose (MTD).
Study: NCT03626571

Intervention type: OTHER
Intervention: 18F-FDG
Description: Hybrid 18F-FDG PET/MR or PET/CT imaging for observational diagnostic purposes.

Intervention type: OTHER
Intervention: 18F-FDG
Description: Hybrid 18F-FDG PET/MR or PET/CT imaging for observational diagnostic purposes.

Intervention type: OTHER
Intervention: 18F-FDG
Description: Hybrid 18F-FDG PET/MR or PET/CT imaging for observational diagnostic purposes.
Study: NCT03385083

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Step count monitoring with consulting
Description: Subject counseled on step counts at initial visit and 2 and 4 weeks

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Step count monitoring without consultation
Description: Subject counseled on step counts at initial visit

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Fitbit tracker
Description: Fitbit tracker given to participant

Intervention type: DEVICE
Group type: PLACEBO_COMPARATOR
Intervention: Fitbit tracker
Description: Fitbit tracker given to participant
Study: NCT03234309

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Magnetic Resonance Imaging
Description: Undergo MRI
Study: NCT01210287

Intervention type: DRUG
Group type: NO_INTERVENTION
Intervention: nucleoside analog reverse transcriptase inhibitor
Description: tablets 100mg qd
Study: NCT03037268

Intervention type: DEVICE
Intervention: Lytro Plenoptic Camera and 28D lens
Description: * visual acuity measured, intraocular pressure obtained, eyes dilated as part of a standard exam for intended patient visit~* screened and consented for study~* subjected to bilateral plenoptic ophthalmoscopy~* mydriatic, single-field fundus images obtained~* images reviewed for quality and diagnostic utility by a masked grader
Study: NCT02285491

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10ml of bupivacaine 0.5%
Description: This is a local anesthetic that will be used to block the ilioinguinal nerve to alleviate pain at the wound site after lscs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 10ml of bupivacaine 0.5%
Description: This is a local anesthetic that will be used to block the ilioinguinal nerve to alleviate pain at the wound site after lscs

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: 10 ml of saline will be injected as a placebo and the investigator and the patient and the data assessor are all blinded to what the patients received.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: 10 ml of saline will be injected as a placebo and the investigator and the patient and the data assessor are all blinded to what the patients received.
Study: NCT02727192

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: PAP (CPAP or ASV)
Description: Patients will be randomized to treatment of Sleep Apnea with a CPAP or control
Study: NCT01529164

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Endostatins (Endostar)
Description: 7.5mg/m2 iv d1-10,repeat every 14 days,until progression or occurrence of untolerated toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oxaliplatin
Description: 85mg/m2 iv d1 ,repeat every 14 days,until progression or occurrence of untolerated toxicity

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leucovorin
Description: 200mg/m2 iv d1 ,repeat every 14 days

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil
Description: 400mg/m2 iv bolus,then 2400mg/m2 continuous infusion for 46 hours,repeated every 14 days,until progression or occurrence of untolerated toxicity
Study: NCT01482117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: single oral administration of 300mg of clopidogrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: single oral administration of 300mg of clopidogrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel
Description: single oral administration of 300mg of clopidogrel

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: single oral administration of 100mg cilostazol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: single oral administration of 100mg cilostazol
Study: NCT03405636

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Xeltis Pulmonary Valved Conduit
Description: RVOT reconstruction
Study: NCT00745576

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SAM-531
Study: NCT01482117

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cilostazol
Description: single oral administration of 100mg cilostazol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel/Cilostazol
Description: single oral administration of 300mg clopidogrel and 100mg cilostazol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel/Cilostazol
Description: single oral administration of 300mg clopidogrel and 100mg cilostazol

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Clopidogrel/Cilostazol
Description: single oral administration of 300mg clopidogrel and 100mg cilostazol
Study: NCT02166606

Intervention type: DEVICE
Intervention: ImageReady MR Conditional Pacing System Implant
Description: Implant according to standard-of-care. No study-specific interventions in that registry.
Study: NCT01896934

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sertraline
Description: 50-200mg daily
Study: NCT02277262

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Biological swine dermis not cross-linked prosthesis positioning in incisional hernia prevention
Description: The mesh placement will be preceded by the plane preparation. The subcutaneous tissue will be dissociated from the anterior rectum-muscles fascia. The retro-muscular rectum muscles plane will be dissected preparing a 5-6 cm pouch necessary to the prosthesis positioning. The mesh will be fixed with at least 8 long-lasting absorbable transfix stitched. The prosthesis will be placed with at least a 5 cm overlap. If the peritoneal plane can be sutured a Jackson-Pratt 10 suction drain will be placed under the prosthesis. A Jackson-Pratt 10 suction drain will always be placed over the prosthesis. Anterior rectum fascia will be closed by emi-continuous monofilament suture with an intermediate-reabsorbable-time suture. Another Jackson-Pratt 10 suction drain will be placed over the anterior fascia if the subcutaneous tissue is thick. No subcutaneous suture will be performed. Skin stapler or interrupted stitches will be used to close the skin plane.

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Direct suture of the anterior abdominal wall fascia
Description: Anterior rectum fascia will be closed by emi-continuous monofilament suture with an intermediate-reabsorbable-time suture. No subcutaneous suture will be performed. Skin stapler or interrupted stitches will be used to close the skin plane.
Study: NCT01781117

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Holmium Laser Enucleation of the Prostate (HoLEP)
Description: Enucleation of the enlarged nodule of prostate and morcellation of the resected tissue.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Holmium laser enucleation system and morcellator
Description: Holmium laser enucleation and morcellation
Study: NCT01787929

Intervention type: PROCEDURE
Group type: OTHER
Intervention: hemiarthroplasty for displaced femoral neck fractures
Description: Hemiarthroplasty is a surgery for displaced femoral neck fractures

Intervention type: PROCEDURE
Group type: OTHER
Intervention: hemiarthroplasty for displaced femoral neck fractures
Description: Hemiarthroplasty is a surgery for displaced femoral neck fractures
Study: NCT00796796

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Temsirolimus

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy

Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Radiation therapy
Study: NCT02316457

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVAC_W_bre1_uID
Description: vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVAC_W_bre1_uID
Description: vaccination

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: IVAC_W_bre1_uID/IVAC_M_uID
Description: vaccination
Study: NCT03732833

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT10109L
Description: MT10109L will be injected into either the LCL, or both the LCL and GL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: MT10109L
Description: MT10109L will be injected into either the LCL, or both the LCL and GL.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: Placebo will be injected into either the GL, or both the LCL and GL.
Study: NCT01687595

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: HerpV and QS-21
Description: HerpV (recombinant human heat shock protein 70 \[rh-Hsc70\] polyvalent peptide complex) in combination with adjuvant QS-21

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: phosphate buffered saline
Study: NCT05541328

Intervention type: OTHER
Intervention: Tisagenlecleucel
Description: The trial cohort is defined as the cohort of patients enrolled in JULIET who were assigned to receive tisagenlecleucel infusion
Study: NCT01880775

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Prilocaine
Description: experimental

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Bupivacaine
Description: marcaine heavy 0.5% 7.5 mg intrathecal
Study: NCT02858661

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Nasopharyngeal swab
Study: NCT00635466

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: laparoscopic surgery for rectal carcinoma
Description: Laparoscopic resection of the rectum with adequate lymphadenectomy is performed according to the General Rules for Clinical and Pathological Studies on Cancer of the Colon, Rectum and Anus edited by the Japanese Society for Cancer of the Colon and Rectum. The extent of lymphadenectomy and site of ligation and division of the inferior mesenteric vessels were decided by the surgeon in charge. Pneumoperitoneal approaches are used to explore the abdomen, mobilize the left side colon, identify critical structures and ligate the vascular pedicle. Mobilization of the rectum, excision of the mesorectum, rectal transection, removal of the specimen, and reconstruction are performed by the pneumoperitoneal approach or the extracorporeal approach via a small incision (\<8 cm).
Study: NCT01026428

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Safinamide + Levodopa
Description: Treatment A: 100mg safinamide once daily administration for 6 days + immediate release levodopa formulation (100 mg levodopa + 25 mg carbidopa = Nacom®).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo + Levodopa
Description: Treatment B: Placebo matching 100mg safinamide once daily administration for 6 days + immediate release levodopa formulation (100 mg levodopa + 25 mg carbidopa = Nacom®).
Study: NCT01400152

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Additional active warming
Description: Chemical heat pad applied to the upper torso
Study: NCT03413449

Intervention type: DIAGNOSTIC_TEST
Intervention: Frailty model
Description: 1. Grip strength~2. 30 second chair sit stand test~3. Psoas muscle area~4. Six minute walk
Study: NCT04054570

Intervention type: OTHER
Intervention: No intervention
Description: No Intervention

Intervention type: OTHER
Intervention: No intervention
Description: No Intervention
Study: NCT04177238

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fruit concentrate - either cherry or blueberry
Description: Fruit (cherry or blueberry concentrate) supplement from a company named Active-Edge (https://active-edge.co.uk/).

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Fruit concentrate - either cherry or blueberry
Description: Fruit (cherry or blueberry concentrate) supplement from a company named Active-Edge (https://active-edge.co.uk/).

Intervention type: DIETARY_SUPPLEMENT
Group type: PLACEBO_COMPARATOR
Intervention: Fruit concentrate - either cherry or blueberry
Description: Fruit (cherry or blueberry concentrate) supplement from a company named Active-Edge (https://active-edge.co.uk/).